Brief: Harrow Inc Reports Fourth-Quarter & Year-End 2024 Audited Financial Results
27/03/2025 21:06
March 27 (Reuters) - Harrow Inc HROW.O: HARROW INC: Q4 CORE EPS $0.40 HARROW HEALTH Q4 CORE GROSS MARGIN 84% HARROW HEALTH Q4 GROSS MARGIN 79% HARROW HEALTH Q4 REVENUE USD 66.8 MILLION VERSUS. IBES ESTIMATE USD 61.8 MILLION Further company coverage: HROW.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Harrow
See all newsHarrow, Inc. reports results for the quarter ended June 30 - Earnings Summary
Harrow Q2 revenue slightly beats estimates
Viatris raises annual profit forecast on branded drug strength
Brief: Harrow Re-Launches Verkazia® (Cyclosporine Ophthalmic Emulsion) 0.1% For Vernal Keratoconjunctivitis, Addressing Significant Unmet Need In Pediatric Eyecare
Harrow Q1 revenue misses analyst estimates